Appian and PSI CRO Form Strategic Partnership to Advance AI-driven Clinical Trial Operations
PR Newswire•28/10/2026•05:00 ET
0
Key Highlights
- ➤Appian (APPN) and PSI CRO launch AI-powered clinical trial site-selection solution
- ➤First joint project automates site identification and selection across geographies and therapeutic areas
- ➤Partnership targets process orchestration across the full clinical trial lifecycle
- ➤PSI’s on-time clinical trial delivery remains above 90% in 2026
- ➤PSI employs over 3,500 people across 58 countries as of September 2026
Expert Statements
Kirill Soldatov, Head of Process Improvement at PSI
“The AI-powered clinical trial site selection solution is an important step in how we are rethinking and connecting our operational processes”
Kirill Soldatov, Head of Process Improvement at PSI
“PSI is known for our ability to deliver complex clinical trials on time. Building a more connected operational model through automation, AI-powered capabilities, and process orchestration within our existing workflows creates a scalable foundation for more predictable, accurate, and timely site selection worldwide, with the goal to further reduce or eliminate non-enrolling sites and patient enrollment delays.”
Alexander Motie, Regional Vice President DACH & Eastern Europe at Appian
“This initial project demonstrates the value AI can create when it is embedded in business processes. The solution helps PSI process information faster with automation and manage processes with greater transparency with orchestration. Through our strategic partnership with PSI, we aim to create a flexible, long-term foundation for further automation and innovation.”
Appian and PSI CRO Form Strategic Partnership to Advance AI-driven Clinical Trial Operations PR Newswire
First joint project launches a broader platform strategy for process orchestration across the clinical trial lifecycle
Get started
Create a free account to read the full story.